We are live on ! Find out more
COCH icon

Envoy Medical

94 hedge funds and large institutions have $362M invested in Envoy Medical in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 7 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

229% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 7

56% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 9

9% more capital invested

Capital invested by funds: $331M → $362M (+$30.8M)

6.7% more ownership

Funds ownership: 80.61%87.31% (+6.7%)

6% more funds holding

Funds holding: 8994 (+5)

Holders
94
Holders Change
+5
Holders Change %
+5.62%
% of All Funds
1.62%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
14
Increased
23
Reduced
7
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CCMU
101
Cheyne Capital Management (UK)
United Kingdom
-$444K -45,307 Closed
PCM
102
Prelude Capital Management
New York
-$153K -15,629 Closed
TRCT
103
Tower Research Capital (TRC)
New York
-$1K -131 Closed

COCH Hedge Fund Activity: Q3 2022 in Review

94 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Envoy Medical (COCH) for Q3 2022, worth a combined $362M — up 9.3% from $331M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new COCH positions and 9 closed out — a net gain of 5 holders — while 23 added to existing stakes and 7 trimmed.

The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $11.1M. The largest seller was Goldman Sachs, cutting an estimated $9.06M.

  • 94 institutional investors held Envoy Medical (COCH) as of Q3 2022, up from 89 in Q2 2022.
  • Funds reported $362M of Envoy Medical stock for Q3 2022, up 9.3% quarter-over-quarter.
  • 14 funds opened new Envoy Medical positions in Q3 2022 and 9 closed out, a net change of +5 holders.
  • The largest Envoy Medical buyer in Q3 2022 was BNP Paribas Financial Markets, an estimated $11.1M added.
  • The largest Envoy Medical seller in Q3 2022 was Goldman Sachs, an estimated $9.06M sold.

Based on aggregated 13F filings for Q3 2022.